Concert Pharmaceuticals (CNCE) vs. Its Rivals Financial Comparison
Concert Pharmaceuticals (NASDAQ: CNCE) is one of 196 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its rivals? We will compare Concert Pharmaceuticals to similar companies based on the strength of its valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.
This table compares Concert Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Concert Pharmaceuticals Competitors||-3,959.43%||-120.79%||-45.11%|
This is a breakdown of current ratings and recommmendations for Concert Pharmaceuticals and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Concert Pharmaceuticals Competitors||468||2232||6126||117||2.66|
Concert Pharmaceuticals presently has a consensus price target of $26.75, suggesting a potential upside of 78.69%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 0.44%. Given Concert Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Concert Pharmaceuticals is more favorable than its rivals.
Insider & Institutional Ownership
61.6% of Concert Pharmaceuticals shares are owned by institutional investors. Comparatively, 46.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 10.1% of Concert Pharmaceuticals shares are owned by company insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Risk & Volatility
Concert Pharmaceuticals has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, Concert Pharmaceuticals’ rivals have a beta of 1.63, suggesting that their average share price is 63% more volatile than the S&P 500.
Valuation and Earnings
This table compares Concert Pharmaceuticals and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Concert Pharmaceuticals||$82,000.00||-$49.11 million||-6.71|
|Concert Pharmaceuticals Competitors||$207.83 million||-$2.34 million||0.16|
Concert Pharmaceuticals’ rivals have higher revenue and earnings than Concert Pharmaceuticals. Concert Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Concert Pharmaceuticals rivals beat Concert Pharmaceuticals on 7 of the 12 factors compared.
Concert Pharmaceuticals Company Profile
Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company’s product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert’s deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.
Receive News & Ratings for Concert Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.